The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread

A. C. Gomes, I. A. Baraniak, A. Lankina, Z. Moulder, P. Holenya, C. Atkinson, G. Tang, T. Mahungu, F. Kern, P. D. Griffiths and M. B. Reeves ()
Additional contact information
A. C. Gomes: Institute of Immunity & Transplantation, UCL
I. A. Baraniak: Institute of Immunity & Transplantation, UCL
A. Lankina: Institute of Immunity & Transplantation, UCL
Z. Moulder: Institute of Immunity & Transplantation, UCL
P. Holenya: JPT Peptide Technologies GmbH
C. Atkinson: Institute of Immunity & Transplantation, UCL
G. Tang: Institute of Immunity & Transplantation, UCL
T. Mahungu: Institute of Immunity & Transplantation, UCL
F. Kern: JPT Peptide Technologies GmbH
P. D. Griffiths: Institute of Immunity & Transplantation, UCL
M. B. Reeves: Institute of Immunity & Transplantation, UCL

Nature Communications, 2023, vol. 14, issue 1, 1-12

Abstract: Abstract Vaccination against human cytomegalovirus (CMV) infection remains high priority. A recombinant form of a protein essential for CMV entry, glycoprotein B (gB), demonstrated partial protection in a clinical trial (NCT00299260) when delivered with the MF59 adjuvant. Although the antibody titre against gB correlated with protection poor neutralising responses against the 5 known antigenic domains (AD) of gB were evident. Here, we show that vaccination of CMV seronegative patients induces an antibody response against a region of gB we term AD-6. Responses to the polypeptide AD-6 are detected in >70% of vaccine recipients yet in

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-36683-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36683-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-36683-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().